When.com Web Search

  1. Ads

    related to: prostate cancer treatment injection name

Search results

  1. Results From The WOW.Com Content Network
  2. Polyestradiol phosphate - Wikipedia

    en.wikipedia.org/wiki/Polyestradiol_phosphate

    Polyestradiol phosphate (PEP), sold under the brand name Estradurin, is an estrogen medication which is used primarily in the treatment of prostate cancer in men. [1] [9] [2] [10] It is also used in women to treat breast cancer, as a component of hormone therapy to treat low estrogen levels and menopausal symptoms, and as a component of feminizing hormone therapy for transgender women.

  3. Leuprorelin - Wikipedia

    en.wikipedia.org/wiki/Leuprorelin

    Lupron injection was approved by the FDA for treatment of advanced prostate cancer on 9 April 1985. [ 45 ] [ 4 ] [ 43 ] [ 44 ] Lupron depot for monthly intramuscular injection was approved by the FDA for palliative treatment of advanced prostate cancer on 26 January 1989.

  4. Degarelix - Wikipedia

    en.wikipedia.org/wiki/Degarelix

    Degarelix, sold under the brand name Firmagon among others, is a hormonal therapy used in the treatment of prostate cancer. [3] [5]Testosterone is a male hormone that promotes growth of many prostate tumours and therefore reducing circulating testosterone to very low levels is often the treatment goal in the management of advanced prostate cancer.

  5. Bicalutamide - Wikipedia

    en.wikipedia.org/wiki/Bicalutamide

    Bicalutamide, sold under the brand name Casodex among others, is an antiandrogen medication that is primarily used to treat prostate cancer. [10] It is typically used together with a gonadotropin-releasing hormone (GnRH) analogue or surgical removal of the testicles to treat metastatic prostate cancer (mPC).

  6. Lutetium (177Lu) vipivotide tetraxetan - Wikipedia

    en.wikipedia.org/wiki/Lutetium_(177Lu)_vipivot...

    Lutetium (177 Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). [5] [6] Lutetium (177 Lu) vipivotide tetraxetan is a targeted radioligand therapy. [6] [8]

  7. Cabazitaxel - Wikipedia

    en.wikipedia.org/wiki/Cabazitaxel

    It is a microtubule inhibitor, [2] and the fourth taxane to be approved as a cancer therapy. [citation needed] Cabazitaxel was developed by Sanofi-Aventis and was approved by the US Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer in June 2010. [5] [6] [7] It is available as a generic medication. [8] [9]